Help the fight against COVID-19




Then you could be eligible to join the AGILE trial which aims to find a treatment for people with COVID-19
Tel: 0151 7064863
Text: COVID to 07342 065915
email: [email protected]
Website: Clinical Research Facility, Liverpool
Tel: 07469 565895
email: [email protected]
Web: Clinical Research Facility, Southampton
Tel: 0161 906 7500
email: [email protected]
Web: Clinical Research Facility, Manchester
Tel: 01772 522031
email: [email protected]
Web: Clinical Research Facility, Lancashire
Tel: 07971367683
email: [email protected]
Web: NIHR Wellcome Kings Clinical Research Facility
More information about treatments being assessed in the AGILE platform study
Molnupiravir. Patient recruitment in Liverpool, Manchester, Lancashire and London community hubs, where prospective patients whose symptoms began within the last 4 days will be contacted, informed about the trial and invited to participate in case they fall ill with COVID-19. You can find more information about Molnupiravir below, and if you have any further questions, please contact [email protected].
VIR-7831/7832. Patient recruitment in Liverpool and Southampton, where prospective patients whose symptoms began within the last 6 days will be contacted, informed about the trial and invited to participate if they have mild to moderate symptoms of COVID-19. You can find more information about VIR-7831/7832 below, and if you have further questions by contacting [email protected] (Liverpool) or [email protected] (Southampton).
Nitazoxanide. Recruitment of healthy volunteers for the first stage of this trial has completed in Liverpool. The second stage of this trial will be carried out in South Africa, recruiting patients with mild/moderate COVID-19 symptoms in Cape Town and Johannesburg. You can find more information about Nitazoxanide if you have further questions by contacting [email protected]